

**REDFLAGS:**  
**Pas de souci, mobilisons:**

# **MOBILISATION EN SITUATIONS EXTREMES**

Xavier Wittebole  
Critical care Department



Cliniques universitaires  
**SAINT-LUC**  
UCL BRUXELLES

**REDFLAGS:**  
**Pas de souci, mobilisons:**

# **MOBILISATION EN SITUATIONS EXTREMES**




Xavier Wittebole  
Critical care Department




**REDFLAGS:**  
**Pas de souci, mobilisons:**

# **MOBILISATION EN SITUATIONS EXTREMES**



Xavier Wittebole  
Critical care Department



Cliniques universitaires  
**SAINT-LUC**  
UCL BRUXELLES

*Je n'ai aucun conflit d'intérêts à déclarer.*



# INTRODUCTION

People enduring a prolonged stay in the ICU on MV are at high risk of long-term physical, psychological, and cognitive disabilities.

Decreasing these risks through rehabilitation activities, including mobilization to prevent rapid muscle wasting, have been endorsed in many international ICU guidelines as part of the ABCDEF bundle.

However, there are many remaining questions such as optimal mobilization frequency, intensity, type, and time, and it is unclear if specific patient groups have different needs.

On top of this, in the TEAM trial, the intervention (increased early mobilization) was associated with increased adverse events.



# Early Active Mobilization during Mechanical Ventilation in the ICU

The TEAM Study Investigators and the ANZICS Clinical Trials Group\*

## Adverse events — no. (%)¶¶

Patients with ≥1 adverse event potentially due to mobilization — no. (%)	34 (9.2)	15 (4.1)	2.55 (1.33–4.89)§	0.005
Adverse events per patient — no. (%)				0.02
0	337 (90.8)	355 (95.9)		
1	19 (5.1)	11 (3.0)		
2	4 (1.1)	2 (0.5)		
≥3	11 (3.0)	2 (0.5)		
Type of adverse events — no. (%)				
Altered blood pressure	13 (3.5)	8 (2.2)		0.27
Cardiac arrhythmia	13 (3.5)	4 (1.1)		0.03
Oxygen desaturation	8 (2.2)	1 (0.3)		0.02
Pain or agitation	4 (1.1)	1 (0.3)		0.37
Removal of invasive line	2 (0.5)	2 (0.5)		1.00
Gastrointestinal	2 (0.5)	1 (0.3)		1.00
Tachypnea	3 (0.8)	0		0.25
Altered neurologic state	1 (0.3)	1 (0.3)		1.00
Other	4 (1.1)	0		0.12

*Hodgson C et al. N Engl J Med.2022;387: 1747-58.*



# Early Active Mobilization during Mechanical Ventilation in the ICU

The TEAM Study Investigators and the ANZICS Clinical Trials Group\*

Adverse events — no. (%)¶¶

Patients with ≥1 adverse event potentially due to mobilization 34 (9.2) 15 (4.1) 2.55 (1.33–4.89)¶ 0.005

Adv

**Table S15. Serious Adverse Events\***

Typ

	Early Mobilization (n=371)	Usual Care (n=370)	P value
Fall to the floor	0 (0)	0 (0)	1.0
Cardiac arrest	0 (0)	0 (0)	1.0
Arrhythmia, no. (%) †	5 (1.3)	0 (0)	0.06
Desaturation, no. (%) ‡	1 (0.3)	1 (0.3)	1.0
Unplanned extubation	0 (0)	0 (0)	1.0
Line removal requiring urgent replacement, no. (%)	0 (0)	0 (0)	1.0
Other, no. (%)§	1 (0.3)	0 (0)	1.0
Tachypnea	3 (0.8)	0	0.25
Altered neurologic state	1 (0.3)	1 (0.3)	1.00
Other	4 (1.1)	0	0.12

Hodgson C et al. *N Engl J Med.*2022;387: 1747-58.

## Exclusion criteria

1. Dependent for activities of daily living in the month prior to current ICU admission (gait aids are acceptable).
2. Documented cognitive impairment.
3. **Proven or suspected acute primary brain pathology** (e.g. traumatic brain injury, stroke, hypoxic brain injury).
4. **Proven or suspected spinal cord injury** or other neuromuscular disease that will result in permanent or prolonged weakness (not including ICU acquired weakness).
5. Has **rest in bed orders** and/or has bilateral non-weight bearing orders for the lower limbs.
6. Life expectancy less than 180 days due to a chronic or underlying medical condition.
7. Death is deemed inevitable as a result of the current illness and either the patient or treating clinical or substitute decision maker are not committed to full active treatment.
8. Unable to communicate in the official local language.
9. This is not the first ICU admission in the index hospital admission.
10. Fulfilled all inclusion criteria and none of the exclusion criteria  $\geq 72$  hours.

*Hodgson C et al. N Engl J Med. 2022;387: 1747-58.*






# Association of active mobilisation variables with adverse events and mortality in patients requiring mechanical ventilation in the intensive care unit: a systematic review and meta-analysis

- Systematic review with frequentist and Bayesian analyses
- RCT active mobilization in the critically ill (on MV) compared with either no mobilization  
mobilization commencing later,  
mobilization at a lower frequency or intensity.
- Primary outcome: number of adverse events that occurred during the implementation of mobilization,
- Secondary outcome: effect of mobilization on mortality.
- After title and abstract screening: 14 440 studies  
Review of 466 full texts,  
67 trials with 7004 participants / 59 trials contributing to the MA.

*Paton M et al. Lancet Respir Med. 2024;12: 386–98.*





# Association of active mobilisation variables with adverse events and mortality in patients requiring mechanical ventilation in the intensive care unit: a systematic review and meta-analysis

In conclusion, our systematic review with frequentist and Bayesian analysis of existing data in a heterogeneous population of critically ill adults showed **no overall effect of mobilisation on the occurrence of adverse events or mortality**.

With mobilisation leading to a **less than 3% incidence of adverse events**, with all but one event reported as transient or resolving with cessation of the intervention or minor medical attention, **our review provides clinicians with reassurance about the safety of providing this treatment**.

*Paton M et al. Lancet Respir Med 2024;12: 386–98.*



# INTRODUCTION

These results look great...

**But**

In those studies, many ICU patients were not enrolled!!!



# INTRODUCTION

These results look great...

**But**


In those studies, many ICU patients were not enrolled!!!

The question is:

**What can we do with the « extreme situations »?**




# Start Here



Rawal D et al.  
Chest.2024; 2(1):100038

# Start Here



## Exclusion Criteria\*

- Significant dose of vasopressors for hemodynamic stability (maintain MAP > 60)
- Mechanically ventilated with FiO2 > .8 and/or PEEP > 12, or acutely worsening respiratory failure
- Neuromuscular paralytics
- Currently in an acute neurological event (CVA, SAH, ICH)
- Unstable spine or extremity fractures
- Grave prognosis, transitioning to comfort care
- Open abdomen, at risk for dehiscence
- Active bleeding process
- Bed rest order

• Vital signs within acceptable parameters

Yes

6. Proceed with standing activities, transferring to chair and gait training

## Exclusion Criteria\*

- Significant dose of vasopressors for hemodynamic stability (maintain MAP > 60)
- Mechanically ventilated with FiO2 > .8 and/or PEEP > 12, or acutely worsening respiratory failure
- Neuromuscular paralytics
- Currently in an acute neurological event (CVA, SAH, ICH)
- Unstable spine or extremity fractures
- Grave prognosis, transitioning to comfort care
- Open abdomen, at risk for dehiscence
- Active bleeding process
- Bed rest order

## Legend

**RASS:** Richmond Agitation Sedation Scale  
**CAM-ICU:** The Confusion Assessment Method for the ICU  
**FiO2:** Fraction of inspired Oxygen  
**PEEP:** Positive End-Expiratory Pressure (cmH2O)  
**MAP:** Mean Arterial Pressure (mmHg)  
**CVA:** Cerebrovascular Accident  
**SAH:** Subarachnoid Hemorrhage  
**ICH:** Intracerebral Hemorrhage  
**CNS:** Central Nervous System  
**Vital sign parameters:** case by case bases.

Rawal D et al.

Chest.2024; 2(1):100038

# Early Mobilization in the ICU

Variable	Exercise in Bed	Exercise Outside Bed
<b>Respiratory parameters</b>		
Endotracheal or tracheostomy tube	Green	Green
SpO <sub>2</sub> , %		
≤ 90	Yellow	Red
> 90	Green	Green
FIO <sub>2</sub>		
≤ 0.6	Green	Green
> 0.6	Yellow	Yellow
Respiratory rate, breaths/min		
> 30	Yellow	Yellow
≤ 30	Green	Green
PEEP, cm H <sub>2</sub> O		
≤ 10	Green	Green
> 10	Yellow	Yellow
Prone positioning	Red	Red

Red = significant risk of an adverse event.

Yellow = potential risk of adverse event, but benefits of EM may outweigh the risk.

Green = low risk of an adverse event.

*Rawal D et al. Chest.2024; 2(1):100038*



# M.V.?

## Early Active Mobilization during Mechanical Ventilation in the ICU

The TEAM Study Investigators and the ANZICS Clinical Trials Group\*

*Hodgson C et al. N Engl J Med.2022;387: 1747-58.*



# M.V. ?

Bayesian subgroup analysis identified a **higher probability of AE** occurring

- with longer durations of mobilization versus shorter durations of mobilization (67.05%; RR 1.12 [95% CI 0.60–1.97]; 18 237 events, 11 studies vs 21.56%; 0.64 [0.20–1.91]; 3391 events, five studies),
- in surgical cohorts versus medical cohorts (77.82%; 1.27 [0.64–2.59]; 8856 events, four studies vs 9.45%; 0.47 [0.14–1.49]; 8173 events, five studies),
- when mobilisation was commenced later rather than earlier in the admission (17.62%; 0.76 [0.35–1.58]; 2672 events, four studies vs 10.95%; 0.69 [0.37–1.58]; 27 920 events, 15 studies),
- **in patients who were extubated when mobilisation commenced versus those mechanically ventilated** (88.42%; 1.72 [0.58–4.93]; 441 events, one study vs 71.43%; 1.16 [0.64–2.05]; 23 272 events, 12 studies];

*Paton M et al. Lancet Respir Med 2024;12: 386–98.*





## Mobilizing Patients in the Intensive Care Unit

Improving Neuromuscular Weakness and Physical Function

*Needham. JAMA.2008;300:1685-90.*









# PRONE ?

Physical rehabilitation while awake, intubated and  
proned for COVID-19-associated severe acute  
respiratory distress syndrome

*Seth B et al. BMJ Case Rep.2024; 17:e251772.*



# Physical rehabilitation while awake, intubated and prone for COVID-19-associated severe acute respiratory distress syndrome

Mechanical ventilation day	1	2	3	4	5	6
Plateau pressure (cmH <sub>2</sub> O)*	25	24	24	22	27	30
ABG (pH/PCO <sub>2</sub> /PaO <sub>2</sub> ) Or VBG* (pH/PCO <sub>2</sub> )	7.25/55/65	7.30/47/86	7.37/44*	7.36/49*	7.36/49*	7.45/40/72
PaO <sub>2</sub> /FiO <sub>2</sub>	65	108	117†	136†	136†	180
FiO <sub>2</sub>	100%	80%	70%	60%	60%	40%
Pain score‡	0	0	0	0	0	0
Sedation status (RASS score)§	+1	0	0	0	-1	0
CAM-ICU	Positive	Negative	Negative	Negative	Negative	Negative
Physical therapy treatment session	None	None	TherEx	TherEx, stretching	TherEx with RB	TherEx with RB, rolling
Occupational therapy treatment session	None	None	TherEx, iPad	ADL	TherEx	ADL, positioning

TherEx: Therapeutic Exercises - RB : resistance band

Seth B et al. *BMJ Case Rep.*2024; 17:e251772.



# Physical rehabilitation while awake, intubated and prone for COVID-19-associated severe acute respiratory distress syndrome

- Severe hypoxaemia / lung protective MV / Prone P / Low level of sedation
- Modified physical rehabilitation interventions by PT and OT.
  - Upper and lower extremity exercises, with and without an exercise resistance band, were conducted, and included hip extension, abduction, hamstring curls and scapular stabilisation exercises.
  - Patient education on repositioning for prevention of pressure sores, assist with patient comfort and prevent potential for shoulder subluxation while in a prone position.
  - Self-care activities, such as brushing hair and hygiene, which included washing hair with a shower cap and face washing, were performed with OT while in a prone position.
  - Both PT and OT assisted with non-pharmacological, multicomponent delirium prevention interventions, such as reorientation, having lights on and blinds open during the day, early mobilisation and cognitive stimulation.

*Seth B et al. BMJ Case Rep.2024; 17:e251772.*





# Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study



**Interpretation** Prone positioning was feasible and effective in rapidly ameliorating blood oxygenation in awake patients with COVID-19-related pneumonia requiring oxygen supplementation. The effect was maintained after resupination in half of the patients. Further studies are warranted to ascertain the potential benefit of this technique in improving final respiratory and global outcomes.

*Coppo A et al. Lancet Respir Med. 2020; 8:765-74.*



# Early Mobilization in the ICU

Variable	Exercise in Bed	Exercise Outside Bed
<b>Respiratory parameters</b>		
Endotracheal or tracheostomy tube	Green	Green
SpO <sub>2</sub> , %		
≤ 90	Yellow	Red
> 90	Green	Green
FIO <sub>2</sub>		
≤ 0.6	Green	Green
> 0.6	Yellow	Yellow
Respiratory rate, breaths/min		
> 30	Yellow	Yellow
≤ 30	Green	Green
PEEP, cm H <sub>2</sub> O		
≤ 10	Green	Green
> 10	Yellow	Yellow
Prone positioning	Yellow	Red !

Red = significant risk of an adverse event.

Yellow = potential risk of adverse event, but benefits of EM may outweigh the risk.

Green = low risk of an adverse event.

*Adapted from Rawal D et al. Chest.2024; 2(1):100038*



# Early Mobilization in the ICU

Variable	Exercise in Bed	Exercise Outside Bed
Cardiovascular parameters		
Hypertensive emergency on treatment	Red	Red
MAP		
More than lower limit of target on no support or low support	Green	Green
Less than target range despite support or causing symptoms	Yellow	Red
More than target on high level support	Yellow	Red
Severe pulmonary hypertension	Yellow	Yellow
Bradycardia		
Requiring treatment or awaiting pacemaker placement	Red	Red
Stable rhythm with a pacemaker	Green	Green
Pacemaker with a dependent rhythm	Yellow	Red
Tachyarrhythmia	Green	Green
Any with ventricular rate < 120 beats/min	Green	Green
Stable with ventricular rate > 150 beats/min	Yellow	Red
Cardiac ischemia (chest pain or EKG changes)	Yellow	Red

Red = significant risk of an adverse event.

Yellow = potential risk of adverse event, but benefits of EM may outweigh the risk.

Green = low risk of an adverse event.

Rawal D et al. Chest.2024; 2(1):100038

# Early Mobilization in the ICU

Variable	Exercise in Bed	Exercise Outside Bed
Cardiovascular parameters		
Hypertensive emergency on treatment	Red	Red
MAP		
More than lower limit of target on no support or low support	Green	Green
Less than target range despite support or causing symptoms	Yellow	Red
More than target on high level support	Yellow	Red
Severe pulmonary hypertension	Yellow	Yellow
Bradycardia		
Requiring treatment or awaiting pacemaker placement	Red	Red
Stable rhythm with a pacemaker	Green	Green
Pacemaker with a dependent rhythm	Yellow	Red
Tachyarrhythmia	Green	Green
Any with ventricular rate < 120 beats/min	Green	Green
Stable with ventricular rate > 150 beats/min	Yellow	Red
Cardiac ischemia (chest pain or EKG changes)	Yellow	Red

Red = significant risk of an adverse event.

Yellow = potential risk of adverse event, but benefits of EM may outweigh the risk.

Green = low risk of an adverse event.

Rawal D et al. Chest.2024; 2(1):100038

# Early Mobilization in the ICU

Variable	Exercise in Bed	Exercise Outside Bed
Devices		
Femoral IABP	Green	Red
ECMO	Green	Red
Ventricular assist device	Green	Green
Pulmonary artery catheter or another cardiac monitoring device	Green	Yellow
Venous and arterial femoral catheters	Green	Green
Femoral sheaths	Yellow	Red
Continuous renal replacement therapy	Green	Green



Red = significant risk of an adverse event.

Yellow = potential risk of adverse event, but benefits of EM may outweigh the risk.

Green = low risk of an adverse event.

*Rawal D et al. Chest.2024; 2(1):100038*

# ECMO ?



Garcia JP et al. *J Thorac Cardiovasc Surg.*2010; 139(6):e137.



# Extracorporeal Membrane Oxygenation in Nonintubated Patients as Bridge to Lung Transplantation

Pat	Age	Gender	Diagnosis	Days on ECMO	Type of Tx	Outcome
1	29	Female	CTEPH	35	BLTx	Discharged, alive, follow-up 14 months after Tx
2	53	Male	PAH, LF, SSc	11	BLTx	Deceased after Tx
3	41	Male	PH, LF due to sarcoidosis	18	BLTx	Discharged, alive, follow-up 6 months after Tx
4	54	Female	IPF	35	BLTx	Discharged, alive, follow-up 4 months after Tx
5	55	Female	IPAH	8	-	Deceased prior to Tx



These data have all the limitations of small case series but they may be viewed as a **proof-of-concept study** demonstrating the feasibility of using ECMO support in non-intubated patients.

*Olsson KM et al. Am J Transpl.2010; 10:2173-8.*

“The management of ECMO patients has been transformed in recent times as a direct result of the **improvement in circuitry**; for example, one of the advantages of the novel, single-lumen ECMO cannulas is the ease of patient positioning. **Patients can sit up or out of bed.** In more experienced centres, patients awaiting lung transplantation **can be extubated and encouraged to ambulate on ECMO** (Fig. 6) [57,58]. This may help **prevent deconditioning and improve long-term outcome** [59]. The realization that patients can be bridged to transplant awake and ambulatory **for months** is beginning to influence care of acute lung failure patients. The ECMO centre at Karolinska Institute, Stockholm, has emphasized for years that awake, spontaneous breathing leads to better results in acute disease in children and adults, although this strategy has not been subjected to controlled investigation. **In addition to the benefits of spontaneous breathing, awake management may avoid many potential complications of intensive care such as excessive sedation, dependent oedema and pressure sores.**”





Picture from C. Hoopes, MD.

MacLaren et al. *Intensive Care Med.* 2012. 38:210–220.





## Ambulatory venovenous extracorporeal respiratory support as a bridge for cystic fibrosis patients to emergent lung transplantation☆



Hayes D et al. *J Cyst Fibros.*2012; 11:40-5.




# Feasibility and Safety of Early Physical Therapy and Active Mobilization for Patients on Extracorporeal Membrane Oxygenation

YOUNGJUN KO,\* YANG HYUN CHO,† YUN HEE PARK,‡ HYUN LEE,§¶ GEE YOUNG SUH,§¶ JEONG HOON YANG,¶||  
Chi-Min PARK,¶# KYEONGMAN JEON,§¶ AND CHI RYANG CHUNG¶



Ko Y et al.  
*ASAIO Journal* 2015; 61:564–568

# Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study



*Abrams D et al. Crit Care.2014; 18:R38.*




# Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study

## Initial Assessments

Assessment of suitability for physical and occupational therapy by medical team  
Functional

Secure all int  
Ensure adequ  
Ensure hemo  
Inspect extra  
•Ensure adequ  
•Tighten all c  
•Assess for le  
Assemble and



**Figure 2 Trends in active physical therapy participation by ECMO patients in the MICU over time.** ECMO extracorporeal membrane oxygenation; MICU Medical Intensive Care Unit; PT physical therapy.

Responsibili  
•Monitoring  
•Monitoring  
•Assisting the patient and providing contact guard: PT, OT

on circuit

Abrams D et al. Crit Care.2014; 18:R38.



# Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study

	Total (n = 35)	BTT (n = 19)	BTR (n = 16)
Maximum PT score (median, IQR)	8 (2 to 8)	8 (6 to 8)	2 (2 to 8)
No. of PT sessions per patient (median, IQR)	5 (1 to 13)	13 (8 to 15)	1.5 (1 to 3.25)
No. of PT sessions/patient/week (median, IQR)	2.8 (0.5 to 7.8)	4.5 (1.4 to 7.8)	1.3 (0.5 to 6.4)
Time from initiation of ECMO to first PT session (days, median, IQR)	2 (1 to 4.5)	2 (1 to 2)	4 (1.75 to 5.75)
No. of ambulatory patients (n, %)	18 (51)	12 (63)	6 (38)
Maximum distance ambulated (ft, median, IQR)	175 (37.5 to 285)	170 (55 to 525)	195 (60 to 398)
Survival to transplantation (n, %)	NA	10 (53)	NA
Survival to discharge (n, %)	23 (66)	9 (90) <sup>a</sup>	14 (88)
Disposition of survivors (n, %)			
Home	13 (57)	4 (44)	9 (64)
Acute rehabilitation	8 (35)	4 (44)	4 (29)
Subacute rehabilitation	2 (9)	1 (11)	1 (7)



Abrams D et al. Crit Care.2014; 18:R38.



# Awake venovenous extracorporeal membrane oxygenation and survival

Retrospective study – 343 patients – 179 survivors

More cirrhosis, tumor, immunosuppression, lung fibrosis in the NS



Rottman FA et al. Front Med (Lausanne). 2024 24;11:1394698.



# Rehabilitation for adult patients undergoing extracorporeal membrane oxygenation

## Abstract

**Background and purpose:** Current information on the latest rehabilitative practices is limited, with previous reviews only covering data up to October 2021, and some considering only patients on awake ECMO or with COVID-19. This review aims to present a concise overview of the latest findings on rehabilitation and highlight emerging trends for patients undergoing ECMO support.

**Methods:** This integrative review was conducted by searching the National Library of Medicine – PubMed database. Two different search strings “extracorporeal membrane oxygenation” AND “rehabilitation” and “extracorporeal membrane oxygenation” AND “physiotherapy” were used to search the published literature. Articles that did not describe rehabilitation techniques, editorials, conference proceedings, letters to editor, reviews and research protocols were excluded. Studies conducted on pediatric populations were also excluded. The search process was completed in December 2023.

**Results:** Thirteen articles were included in the final analysis. Eight hundred and thirty-nine patients aged between 27 and 63 years were included; 428 were men (51%). In 31% of the included studies, patients had COVID-19; nevertheless, rehabilitative activities did not differ from non-COVID-19 patients. In most studies, rehabilitation commenced within the first 48–96 h and consisted of progressive exercise and out-of-bed activities such as sitting, standing and walking.

**Conclusion:** Current practice focuses on rehabilitative protocols that incorporate exercise routines with progressive intensity, greater emphasis on out-of-bed activities, and a multidisciplinary approach to patient mobilization.

*Polastri M et al. Perfusion.2024; 39(S1):S115-S126*



# Early Mobilization in the ICU

Variable	Exercise in Bed	Exercise Outside Bed
Devices		
Femoral IABP	Green	Red
ECMO	Green	Yellow !
Ventricular assist device	Green	Green
Pulmonary artery catheter or another cardiac monitoring device	Green	Yellow
Venous and arterial femoral catheters	Green	Green
Femoral sheaths	Yellow	Red
Continuous renal replacement therapy	Green	Green

E.V.D. ???


- Red = significant risk of an adverse event.
- Yellow = potential risk of adverse event, but benefits of EM may outweigh the risk.
- Green = low risk of an adverse event.

*Rawal D et al. Chest.2024; 2(1):100038*



# E.V.D. ?



EVD entering the lateral ventricle through a burrhole



# E.V.D. ?



# E.V.D. ?



# E.V.D. ?

Specific surveillance:

- Hemodynamic
- Neurologic



# Early Mobilization in the ICU

Variable	Exercise in Bed	Exercise Outside Bed
Devices		
Femoral IABP	Green	Red
ECMO	Green	Yellow !
Ventricular assist device	Green	Green
Pulmonary artery catheter or another cardiac monitoring device	Green	Yellow
Venous and arterial femoral catheters	Green	Green
Femoral sheaths	Yellow	Red
Continuous renal replacement therapy	Green	Green

E.V.D.



- Red = significant risk of an adverse event.
- Yellow = potential risk of adverse event, but benefits of EM may outweigh the risk.
- Green = low risk of an adverse event.

*Adapted from Rawal D et al. Chest.2024; 2(1):100038*

# Early Mobilization in the ICU

Variable	Exercise in Bed	Exercise Outside Bed
Neurologic parameters		
Level of consciousness, RASS score		
-1 to +1	Green	Green
-2 to +2	Yellow	Yellow
< -2	Yellow	Red
> +2	Red	Red
Active management of elevated ICP	Red	Red
Uncontrollable seizures	Red	Red
Spinal precautions	Red	Red

Red = significant risk of an adverse event.

Yellow = potential risk of adverse event, but benefits of EM may outweigh the risk.

Green = low risk of an adverse event.

*Rawal D et al. Chest.2024; 2(1):100038*



# Early Mobilization in the ICU

Variable	Exercise in Bed	Exercise Outside Bed
Neurologic parameters		
Level of consciousness, RASS score		
-1 to +1		
-2 to +2		
< -2		
> +2		
Active mandibular		
Uncontrollable		
Spinal precautions		

RASS score			
Richmond Agitation & Sedation Scale			CAM-ICU
Score	Description		
+4	Combative	Violent, immediate danger to staff	RASS ≥ -2 Proceed to CAM-ICU assessment
+3	Very agitated	Pulls at or removes tubes, aggressive	
+2	Agitated	Frequent non-purposeful movements, fights ventilator	
+1	Restless	Anxious, apprehensive but movements not aggressive or vigorous	
0	Alert & calm		
-1	Drowsy	Not fully alert, sustained awakening to voice (eye opening & contact >10 secs)	RASS < -2 STOP Recheck later
-2	Light sedation	Briefly awakens to voice (eye opening & contact < 10 secs)	
-3	Moderate sedation	Movement or eye-opening to voice (no eye contact)	
-4	Deep sedation	No response to voice, but movement or eye opening to physical stimulation	
-5	Un-rousable	No response to voice or physical stimulation	



Flower D et al. Crit Care Med 2014; 42(1):100038

# Early Mobilization in the ICU

Variable	Exercise in Bed	Exercise Outside Bed
Neurologic parameters		
Level of consciousness, RASS score		
-1 to +1	Green	Green
-2 to +2	Yellow	Yellow
< -2	Yellow	Yellow !
> +2	Red	Red
Active management of elevated ICP	Red	Red
Uncontrollable seizures	Red	Red
Spinal precautions	Red	Red

Red = significant risk of an adverse event.

Yellow = potential risk of adverse event, but benefits of EM may outweigh the risk.

Green = low risk of an adverse event.

*Adapted from Rawal D et al. Chest.2024; 2(1):100038*



# T.B.I. ?

Assessing the impact of early progressive mobilization on moderate-to-severe traumatic brain injury: a randomized controlled trial

*Yen HC et al. Critical Care.2024; 28:172.*



# Assessing the impact of early progressive mobilization on moderate-to-severe traumatic brain injury: a randomized controlled trial



RCT – 65 patients

EPM (Early Progressive Mobilization) vs EPUP (Early Progressive Uprise Mobilization)

Primary outcome: the Perme ICU Mobility Score (0-32)

Similar GCS (9) – ISS: 24 vs 29

ICP: 51% vs 43%

Craniectomy: 10 vs 12

*Yen HC et al. Critical Care.2024; 28:172.*




# Assessing the impact of early progressive mobilization on moderate-to-severe traumatic brain injury: a randomized controlled trial



RCT – 65  
EPM (Early  
Primary o

Similar G  
ICP: 51%  
Craniecto

obilization)



Time to first rehabilitation intervention (days), mean ± SD

2.05 ± 1.02

2.03 ± 0.88

0.927<sup>a</sup>

Time to first out-of-bed mobilization (days), mean ± SD


4.31 ± 1.25

12.98 ± 6.19

< 0.001<sup>a\*</sup>

Yen HC et al. *Critical Care*.2024; 28:172.

# Early versus delayed mobilization after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis of efficacy and safety



- Early (within 7 days) vs late mobilization

- lack of high-quality studies,
- varying protocols,
- statistical heterogeneity,




The level of evidence for recommendations regarding EM in patients with aSAH remains low.

Morello A et al. *Neurosurg Focus*.2023; 55(6):E11.




## mRS at Discharge

Study or Subgroup	Early Mobilization			Control			Weight	Mean Difference IV, Random, 95% CI	Year
	Mean	SD	Total	Mean	SD	Total			
Foudhaili et al. 2023 <sup>27</sup>	2	1.48	31	1	2.22	57	33.5%	1.00 [0.22, 1.78]	2023
Yokobatake et al. 2022 <sup>24</sup>	3	2.22	56	4	2.22	55	33.3%	-1.00 [-1.83, -0.17]	2022
Okamura et al. 2021 <sup>23</sup>	1.5	1.4	13	4.1	0.8	22	33.2%	-2.60 [-3.43, -1.77]	2021
<b>Total (95% CI)</b>			<b>100</b>			<b>134</b>	<b>100.0%</b>	<b>-0.86 [-2.93, 1.20]</b>	
Heterogeneity: $\tau^2 = 3.16$ ; $\chi^2 = 38.85$ , $df = 2$ ( $P < 0.00001$ ); $I^2 = 95\%$									
Test for overall effect: $Z = 0.82$ ( $P = 0.41$ )									




## Clinical Vasospasm

Study or Subgroup	Early Mobilization		Control			Weight	Odds Ratio M-H, Random, 95% CI	Year
	Events	Total	Events	Total	Weight			
Foudhaili et al. 2023 <sup>27</sup>	11	31	25	57	14.5%	0.70 [0.29, 1.74]	2023	
Takara et al. 2022 <sup>26</sup>	22	228	35	282	16.9%	0.75 [0.43, 1.33]	2022	
Yang et al. 2022 <sup>25</sup>	0	34	0	34		Not estimable	2022	
Yokobatake et al. 2022 <sup>24</sup>	2	56	7	55	9.4%	0.25 [0.05, 1.28]	2022	
Okamura et al. 2021 <sup>23</sup>	1	13	3	22	6.0%	0.53 [0.05, 5.68]	2021	
Karic et al. 2017 <sup>22</sup>	12	84	21	72	15.3%	0.40 [0.18, 0.90]	2017	
Milovanovic et al. 2017 <sup>21</sup>	25	34	9	31	13.1%	6.79 [2.29, 20.14]	2016	
Riordan et al. 2015 <sup>19</sup>	3	22	27	58	11.3%	0.18 [0.05, 0.68]	2015	
Shimamura et al. 2014 <sup>17</sup>	8	25	23	43	13.5%	0.41 [0.15, 1.15]	2014	
<b>Total (95% CI)</b>		<b>527</b>		<b>654</b>	<b>100.0%</b>	<b>0.63 [0.31, 1.26]</b>		
Total events	84		150					
Heterogeneity: Tau <sup>2</sup> = 0.67; Chi <sup>2</sup> = 25.21, df = 7 (P = 0.0007); I <sup>2</sup> = 72%								
Test for overall effect: Z = 1.31 (P = 0.19)								




## Length of Stay (days)

Study or Subgroup	Early Mobilization			Control			Weight	Mean Difference IV, Random, 95% CI	Year
	Mean	SD	Total	Mean	SD	Total			
Foudhaili et al. 2023 <sup>27</sup>	13	3.7	31	15	3.33	57	27.2%	-2.00 [-3.56, -0.44]	2023
Yokobatake et al. 2022 <sup>24</sup>	26	2.96	56	39	17.78	55	20.5%	-13.00 [-17.76, -8.24]	2022
Yang et al. 2022 <sup>25</sup>	19.8	8.1	34	25.9	11	34	20.9%	-6.10 [-10.69, -1.51]	2022
Okamura et al. 2021 <sup>23</sup>	25.7	3.7	13	50.1	37.5	22	5.4%	-24.40 [-40.20, -8.60]	2021
Olkowski et al. 2015 <sup>18</sup>	12.8	5.7	55	15.7	5.6	38	26.0%	-2.90 [-5.23, -0.57]	2015
<b>Total (95% CI)</b>			<b>189</b>			<b>206</b>	<b>100.0%</b>	<b>-6.56 [-10.64, -2.47]</b>	
Heterogeneity: $\tau^2 = 15.33$ ; $\chi^2 = 26.98$ , $df = 4$ ( $P < 0.0001$ ); $I^2 = 85\%$									
Test for overall effect: $Z = 3.14$ ( $P = 0.002$ )									



## Radiological Vasospasm

	Early Mobilization		Control			Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	
Yang et al. 2022 <sup>25</sup>	5	34	14	34	10.8%	0.25 [0.08, 0.79]	2022	
Yokobatake et al. 2022 <sup>24</sup>	16	56	23	55	22.6%	0.56 [0.25, 1.23]	2022	
Karic et al. 2017 <sup>22</sup>	50	84	47	72	31.9%	0.78 [0.41, 1.50]	2017	
Olkowski et al. 2015 <sup>18</sup>	25	55	21	38	20.6%	0.67 [0.29, 1.55]	2015	
Riordan et al. 2015 <sup>19</sup>	14	22	35	58	14.1%	1.15 [0.42, 3.18]	2015	
<b>Total (95% CI)</b>		<b>251</b>		<b>257</b>	<b>100.0%</b>	<b>0.65 [0.44, 0.97]</b>		
Total events	110		140					
Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 4.32, df = 4 (P = 0.36); I <sup>2</sup> = 7%								
Test for overall effect: Z = 2.11 (P = 0.03)								



Morello A et al. Neurosurg Focus.2023; 55(6):E11.

# Early versus delayed mobilization after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis of efficacy and safety

- No difference in neurological outcome and clinical vasospasm
- Decrease in radiological vasospasm and HLOS
- Trend towards decreased use of permanent CSF shunting and LD (but no effect on EVD devices used and hydrocephalus)
- No effect on 30-day mortality, rates of pneumonia and DVT

*Morello A et al. Neurosurg Focus.2023; 55(6):E11.*



# Early versus delayed mobilization after aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis of efficacy and safety

- No difference in neurological outcome and clinical vasospasm
- Decrease in radiological vasospasm and HLOS
- Trend towards decreased use of permanent CSF shunting and LD (but no effect on EVD devices used and hydrocephalus)
- No effect on 30-day mortality, rates of pneumonia and DVT

*“The currently available data indicated that mobilization within the first 5 days after aneurysm repair was **feasible and safe** without significant excessive adverse events, that **neurological outcome with EM was almost certainly not worse** than with prolonged immobilization, and that there was likely at least some reduction in length of hospital stay.”*

Morello A et al. *Neurosurg Focus*.2023; 55(6):E11.



# Association Between Early Mobilization and Functional Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage: A Multicenter Retrospective Propensity Score-Matched Study

**Table 2 Primary and secondary outcomes after propensity score matching**

	Early mobilization group (n = 122)	Delayed mobilization group (n = 122)	P value	Risk difference (95% CI)
<b>Primary outcome</b>				
Favorable outcome (mRS score 0–2), n (%)	99 (81.1)	64 (52.5)	< 0.001	28.7 (17.4 to 39.9)
<b>Secondary outcome</b>				
Discharge to home, n (%)	95 (77.9)	55 (45.1)	< 0.001	32.8 (21.3 to 44.3)
Walking independence at discharge, n (%)	102 (83.6)	69 (56.6)	< 0.001	27.0 (16.1 to 38.0)
Length of hospital stay (days), median (IQR)	27.0 (21.0–35.0)	37.5 (27.3–52.0)	< 0.001	
Lower limb paralysis, n (%)	24 (19.7)	48 (39.3)	0.001	– 19.7 (– 30.8 to – 8.5)
Higher brain dysfunction, n (%)	47 (38.5)	67 (54.9)	0.015	– 16.4 (– 28.7 to – 4.0)
<b>Complication, n (%)</b>				
Symptomatic cerebral vasospasm	5 (4.1)	27 (22.1)	< 0.001	– 18.0 (– 26.2 to – 9.9)
Secondary hydrocephalus with shunt surgery	12 (9.8)	20 (16.4)	0.184	– 6.6 (– 15.0 to 1.9)
Deep venous thrombosis	2 (1.6)	4 (3.3)	0.684	– 1.6 (– 5.5 to 2.2)
Pneumonia	4 (3.3)	19 (15.6)	0.002	– 12.3 (– 19.5 to – 5.1)
Heart failure	1 (0.8)	9 (7.4)	0.019	– 6.6 (– 11.5 to – 1.7)
Symptomatic epilepsy	1 (0.8)	3 (2.5)	0.622	– 1.6 (– 4.8 to 1.5)
Meningitis	0 (0.0)	8 (6.6)	0.007	– 6.6 (– 10.9 to – 2.2)
Urinary tract infection	1 (0.8)	3 (2.5)	0.622	– 1.6 (– 4.8 to 1.5)

Takara H et al. *Neurocrit Care*.2024.

# Association Between Early Mobilization and Functional Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage: A Multicenter Retrospective Propensity Score-Matched Study

**Table 2 Primary and secondary outcomes after propensity score matching**


	Early mobilization group (n = 122)	Delayed mobilization group (n = 122)	P value	Risk difference (95% CI)
<b>Primary outcome</b>				
Favorable outcome (mRS score 0–2), n (%)	99 (81.1)	64 (52.5)	< 0.001	28.7 (17.4 to 39.9)
<b>Secondary outcome</b>				
Discharge to home, n (%)	95 (77.9)	55 (45.1)	< 0.001	32.8 (21.3 to 44.3)
Walking independence at discharge, n (%)	102 (83.6)	69 (56.6)	< 0.001	27.0 (16.1 to 38.0)
Length of hospital stay (days), median (IQR)	27.0 (21.0–35.0)	37.5 (27.3–52.0)	< 0.001	
Lower limb paralysis, n (%)	24 (19.7)	48 (39.3)	0.001	– 19.7 (– 30.8 to – 8.5)
Higher brain dysfunction, n (%)	47 (38.5)	67 (54.9)	0.015	– 16.4 (– 28.7 to – 4.0)
<b>Complication, n (%)</b>				
Symptomatic cerebral vasospasm	5 (4.1)	27 (22.1)	< 0.001	– 18.0 (– 26.2 to – 9.9)
Secondary hydrocephalus with shunt surgery	12 (9.8)	20 (16.4)	0.184	– 6.6 (– 15.0 to 1.9)
Deep venous thrombosis	2 (1.6)	4 (3.3)	0.684	– 1.6 (– 5.5 to 2.2)
Pneumonia	4 (3.3)	19 (15.6)	0.002	– 12.3 (– 19.5 to – 5.1)
Heart failure	1 (0.8)	9 (7.4)	0.019	– 6.6 (– 11.5 to – 1.7)
Symptomatic epilepsy	1 (0.8)	3 (2.5)	0.622	– 1.6 (– 4.8 to 1.5)
Meningitis	0 (0.0)	8 (6.6)	0.007	– 6.6 (– 10.9 to – 2.2)
Urinary tract infection	1 (0.8)	3 (2.5)	0.622	– 1.6 (– 4.8 to 1.5)

**11 DAYS vs 17 DAYS**


*Takara H et al. Neurocrit Care.2024.*

# EARLY MOBILIZATION OF PATIENTS WITH SUBARACHNOID HAEMORRHAGE: A NATIONAL SURVEY OF FRENCH INTENSIVE CARE UNITS

Is sitting out of bed allowed within the first 5 days of securing the aneurysm ?



What complications do you think could be associated with the standing of patients admitted for SAH?




Foudhaili R et al. *J Rehabil Med.* 2024; 56: jrm17734




# EARLY MOBILIZATION OF PATIENTS WITH SUBARACHNOID HAEMORRHAGE: A NATIONAL SURVEY OF FRENCH INTENSIVE CARE UNITS

Is sitting out of bed allowed within the first 5 days of securing the aneurysm ?



**Conclusion:** Mobilization of patients with subarachnoid haemorrhage is heterogeneous among French neuro-intensive care units and several barriers preclude improvement of mobilization practices. Interventional studies assessing mobilization practices, as well as education and training of staff, are crucial to ensure the proper management of patients with subarachnoid haemorrhage and to improve outcomes.




What complications do you think could be associated with the standing of patients admitted for SAH?



Foudhaili R et al. J Rehabil Med. 2024; 56: jrm17734

# PRONE and ICP

## Does Prone Positioning Increase Intracranial Pressure? A Retrospective Analysis of Patients with Acute Brain Injury and Acute Respiratory Failure



29 patients – 119 episodes of PP – Mean duration of PP: 2,5days  
More ICP > 20 and more CPP < 70 durin PP

*Roth C et al. Neurocrit Care.2014; 21:186–191*



# PRONE and ICP



## Invasive Mechanical Ventilation in Traumatic Brain Injured Patients with Acute Respiratory Failure

Ventilatory Parameters and Strategies	Recommended Ventilatory Targets in Patients with TBI [2, 15]	Recommended Ventilatory Targets in Patients with ARDS [26]
Tidal volume	6-9 ml/kg IBW (strong recommendation)	4-8 ml/kg IBW (strong recommendation)
PEEP	Reasonable to set PEEP level monitoring ICP in order to avoid significant ICP increase due to PEEP	Higher rather than lower levels of PEEP are suggested in patients with moderate or severe ARDS (conditional recommendation)
Plateau Pressure	Plateau pressure <30 cm H <sub>2</sub> O (strong recommendation)	Plateau pressure <30 cm H <sub>2</sub> O (strong recommendation)
PaO <sub>2</sub>	Normoxia: PaO <sub>2</sub> ranges from 80 to 120 mm Hg (strong recommendation)	PaO <sub>2</sub> 55-88 mmHg accepted
PaCO <sub>2</sub>	Normocapnia: PaCO <sub>2</sub> ranges from 35 to 45 mm Hg (strong recommendation)	Permissive hypercapnia accepted
Prone positioning	Reasonable to attempt in case of severe hypoxemia with strict neuromonitoring	Recommended when PaO <sub>2</sub> /FiO <sub>2</sub> ratio <150 for more than 12 hours (strong recommendation)
Recruitment maneuvers	Reasonable to attempt in case of severe hypoxemia with strict neuromonitoring	RMs are suggested in patients with severe ARDS (conditional recommendation)
ECMO	Only in specific cases, such as rescue therapy when conventional treatment fails	Might be used as rescue therapy (additional evidence is necessary to make a definitive recommendation for or against the use of ECMO)

*Racca F et al. Rev Recent Clin Trials. 2023;18(1):3-11.*

# Early Mobilization in the ICU

Variable	Exercise in Bed	Exercise Outside Bed
Other considerations		
Unstable major fractures	Yellow	Red
Pelvic	Yellow	Red
Spinal	Yellow	Red
Lower limb long bone	Yellow	Red
Large open surgical wounds	Green	Red
Chest	Green	Red
Abdomen	Green	Red
Known uncontrolled active bleeding	Red	Red

Red = significant risk of an adverse event.

Yellow = potential risk of adverse event, but benefits of EM may outweigh the risk.

Green = low risk of an adverse event.

*Rawal D et al. Chest.2024; 2(1):100038*



# Assessing the safety of physical rehabilitation in critically ill patients: a Delphi study

Did an adverse event occur during or immediately after the mobilisation treatment (as per the definitions below)?	Yes*: <input type="checkbox"/>	No: <input type="checkbox"/>
*If YES please: a) specify adverse event on questionnaire below; b) give a classification at the end:		
<b>Unsafe change in physiological observations where (one or more of the following occurred):</b>		
<ul style="list-style-type: none"> <li>it stopped the mobilisation treatment</li> <li>it did not resolve with rest</li> <li>it caused symptoms (e.g. syncope (fainting) due to cardiovascular deterioration) and/or haemodynamic instability</li> <li>it requires a new treatment or a substantial increase in existing treatment (e.g. unplanned increase in ventilator support)</li> <li>it went above/below a pre-specified patient-specific target range for an adverse event</li> </ul>		
Bradycardia <input type="checkbox"/>	Hypotension <input type="checkbox"/>	Tachypnoea <input type="checkbox"/>
Tachycardia <input type="checkbox"/>	Hypertension <input type="checkbox"/>	Bradypnoea <input type="checkbox"/>
Arterial oxygen desaturation, or arterial blood gases with hypoxia and/or hypercapnia <input type="checkbox"/>		
<b>Airway</b>		
Any unplanned displacement, disruption or dysfunctioning of endotracheal tube or tracheostomy. If yes: <input type="checkbox"/>		
<ul style="list-style-type: none"> <li>Airway was removed completely <input type="checkbox"/></li> <li>Reintubation was required <input type="checkbox"/></li> </ul>		
<b>Cardiovascular</b>		
Myocardial infarction/ischæmia <input type="checkbox"/>	Embolisation of a thrombosis (dislodging a blood clot) <input type="checkbox"/>	
Any new arrhythmia (ignore arrhythmias that are not clinically concerning). If yes: <input type="checkbox"/>		
<ul style="list-style-type: none"> <li>arrhythmia associated with symptoms and/or haemodynamic instability <input type="checkbox"/></li> <li>arrhythmia does not resolve with rest <input type="checkbox"/></li> <li>arrhythmia requires treatment <input type="checkbox"/></li> </ul>		
<b>Neurological</b>		
Seizure <input type="checkbox"/>	Stroke <input type="checkbox"/>	Any other neurological deterioration <input type="checkbox"/>
If any of the above occurred, please specify if:		
<ul style="list-style-type: none"> <li>Neurological deterioration was persistent <input type="checkbox"/></li> <li>Neurological deterioration requires imaging/treatment <input type="checkbox"/></li> </ul>		
<b>Any indwelling devices, lines, tubes or drains:</b>		
<ul style="list-style-type: none"> <li>were disrupted or dysfunctioning <input type="checkbox"/></li> <li>were removed completely <input type="checkbox"/></li> </ul>		
Please specify which tubes, drains, lines (e.g. if attached to organ support):		
<b>Falls and injuries</b>		
Any fall (which also includes if fall was averted/lessened by intervention of staff). If yes: <input type="checkbox"/>		
<ul style="list-style-type: none"> <li>The fall caused physical injury <input type="checkbox"/></li> <li>The fall caused psychological injury <input type="checkbox"/></li> <li>The fall required treatment <input type="checkbox"/></li> </ul>		
Please specify the extent of the fall (e.g. fall to chair or the floor):		
Any injuries to patient e.g. changes to skin integrity, disruption to wounds/dressings/surgical incisions. If yes: <input type="checkbox"/>		
<ul style="list-style-type: none"> <li>Injury not recovered by 24 hours <input type="checkbox"/></li> <li>Injury delays other treatment plan <input type="checkbox"/></li> </ul>		
Staff injured related to patient mobilisation <input type="checkbox"/>		
<b>Other</b>		
Death <input type="checkbox"/>	Cardiac and/or respiratory arrest <input type="checkbox"/>	
Requires acute surgery as a result of mobilisation <input type="checkbox"/>		
Any other patient deterioration thought to be related to mobilisation. If yes: <input type="checkbox"/>		
<ul style="list-style-type: none"> <li>Mobilisation had to be stopped early due to an unsafe event <input type="checkbox"/></li> <li>Adverse events that did not resolve with rest <input type="checkbox"/></li> <li>Mobilisation leads to starting new organ support modalities <input type="checkbox"/></li> </ul>		
Please specify:		
<b>Adverse event classification</b>		
a) Adverse event that stopped mobilisation <input type="checkbox"/>		
b) Adverse event that did not cause mobilisation to stop, but lead to further consequences <input type="checkbox"/>		
c) Adverse event with serious consequences (increased length of stay, surgery, death) <input type="checkbox"/>		
NB If > 1 adverse event occurred, please specify classification (a, b or c) for each one below:		

Do you want to mobilise a patient out of bed receiving vasoactive drugs?			
<b>Principles</b>			
<ol style="list-style-type: none"> <li>Assess risk using a stepwise approach: only progress mobilisation if vital signs remain stable.</li> <li>Specific doses of vasoactive drugs to indicate when risk changes cannot be specified - dose should be taken within the context of individual patient risk factors.</li> <li>The heart rate and blood pressure for different levels of risk will vary according to specific patient characteristics.</li> <li>This tool is not designed for brain injured patients with specific haemodynamic targets.</li> </ol>			
<b>Please consider:</b>			
<b>Vasoactive drug specific</b>	<b>Cardiovascular</b>	<b>Other indicators</b>	
<ul style="list-style-type: none"> <li>Dose and recent change in dose</li> <li>Number and particular types of vasoactive drugs.</li> <li>Reason for use.</li> </ul>	<ul style="list-style-type: none"> <li>Recent trends in heart rate and blood pressure.</li> <li>Heart rhythm.</li> <li>Signs of inadequate perfusion.</li> </ul>	<ul style="list-style-type: none"> <li>Disease specific factors</li> <li>Premorbid functional status</li> <li>Degree of cooperativeness of patient</li> </ul>	
<b>STOP: mobilisation is CONTRAINDICATED (IF YES, TURN OVER FOR MORE DETAILS)</b>			
<ul style="list-style-type: none"> <li>Failure to achieve satisfactory cardiovascular stability on any dose of vasoactive drugs?</li> <li>Pulmonary embolus?</li> <li>Aortic dissection?</li> </ul>			
<b>TALK TO THE LEAD/SENIOR CLINICIAN BEFORE MOBILISATION: Caution because mobilisation has become HIGHER risk (IF YES, TURN OVER FOR MORE DETAILS)</b>			
<b>Vasoactive drug specific</b>	<b>Cardiovascular</b>	<b>Examples of other things to consider</b>	
<ul style="list-style-type: none"> <li>Two or more vasoactive drugs?</li> <li>Medium dose of vasoactive drugs or above?</li> <li>Any recent increase in dose?</li> <li>Unsecure central venous access?</li> <li>Vasoactive drugs used for patient pathology rather than counteracting other treatments such as an epidural?</li> </ul>	<ul style="list-style-type: none"> <li>Cardiovascular instability?</li> <li>Recent onset arrhythmia?</li> <li>Hypovolaemia/inadequate perfusion?</li> <li>Impaired cardiac output?</li> <li>Pericardial tamponade/pulmonary support (e.g. pacing)?</li> <li>Myocardial ischaemia/infarction?</li> </ul>	<ul style="list-style-type: none"> <li>Staff inexperience?</li> <li>Patient's first mobilisation treatment on a vasopressor? Previous adverse events during mobilisation?</li> <li>Adolescent?</li> <li>Severe dyspnoea? Higher ventilation support?</li> <li>Autonomic dysregulation?</li> <li>Active organ ischaemia?</li> <li>ECMO / Intra-aortic balloon pump?</li> <li>Inadequate analgesia? If mobilisation has been specifically limited post-surgery (e.g. open abdomen) or because of injuries?</li> <li>Reduced conscious level?</li> </ul>	
There may be other things in your environment that will add to risk.			
<b>Guidance tool to aid risk assessment for mobilising patients out of bed receiving vasoactive drugs</b>			
<b>Definitions:</b>			
<ul style="list-style-type: none"> <li>Mobilising out of bed: away from the support of the bed i.e. sitting on the edge of bed, moving from sitting to standing, transferring to a chair, marching on the spot and walking.</li> <li>Vasoactive drugs: Continuous infusions primarily used to support cardiac function e.g. to maintain cardiac output, organ perfusion and blood pressure, e.g. noradrenaline, adrenaline, dobutamine.</li> <li>For use with general ICU patients. This tool is not designed for brain injured patients with specific haemodynamic targets.</li> </ul>			
<b>Overriding principles:</b>			
<ol style="list-style-type: none"> <li>Risk should be assessed using a stepwise approach, with progression of mobilisation occurring if vital signs remain stable.</li> <li>Specific cut off doses of vasoactive drugs for different levels of risk cannot be specified, since there are multiple issues that must be considered at the same time. The doses given here are guidance, are not absolute and dose should be taken in the context of individual patient risk factors.</li> <li>Target ranges for heart and blood pressure for different levels of risk vary according to specific patient characteristics.</li> </ol>			
<b>Types of indicators of risk to consider:</b>			
<b>Vasoactive drug specific</b>	<b>Cardiovascular</b>	<b>Other indicators</b>	
<ul style="list-style-type: none"> <li>Dose and recent change in dose</li> <li>Number and particular types of vasoactive drugs.</li> <li>Reason for use.</li> </ul>	<ul style="list-style-type: none"> <li>Recent trends in heart rate and blood pressure.</li> <li>Heart rhythm.</li> <li>Signs of inadequate perfusion (e.g. lactate, central venous oxygen saturation).</li> </ul>	<ul style="list-style-type: none"> <li>Disease specific factors</li> <li>Premorbid functional status</li> <li>Degree of cooperativeness of patient</li> </ul>	
<b>Indicators that mobilisation is CONTRAINDICATED</b>			
<b>Vasoactive drug specific</b>	<b>Cardiovascular</b>	<b>Other indicators</b>	
<ul style="list-style-type: none"> <li>(Possible guidance dose, in the region of adrenaline/epinephrine dose &gt; 0.5 mcg/kg/min** required to maintain cardiovascular stability - see principle 2 above.)</li> </ul>	<ul style="list-style-type: none"> <li>Failure to achieve satisfactory cardiovascular stability on any dose of vasoactive drugs.</li> <li>Submassive or massive pulmonary embolus.</li> <li>Untreated acute aortic dissection.</li> </ul>	<ul style="list-style-type: none"> <li>Severe respiratory failure e.g. requiring deep sedation +/- paralysis and lung protective ventilation.</li> <li>Active cooling</li> <li>Unstable fractures or spinal injuries</li> </ul>	
<b>Indicators that a patient has become HIGHER risk (More caution required, for instance by consulting with a lead/senior clinician or gaining specific sign off before mobilising.)</b>			
<b>Vasoactive drug specific</b>	<b>Cardiovascular</b>	<b>Other indicators</b>	
<ul style="list-style-type: none"> <li>Two or more vasoactive drugs.</li> <li>Medium dose of vasoactive drugs or above (possible guidance doses, in the region of noradrenaline/epinephrine or adrenaline/epinephrine dose &gt; 0.2, dobutamine dose &gt; 10 mcg/kg/min** - see principle 2 above).</li> <li>Any recent increase in dose or dose needs to be increased during mobilisation.</li> <li>Unsecure central venous access with possibility of occluding/disconnecting line during mobilisation.</li> <li>Vasoactive drugs used for patient pathology (e.g. septic shock) rather than counteracting other treatments (e.g. epidural).</li> </ul>	<ul style="list-style-type: none"> <li>Cardiovascular instability.</li> <li>Difficulty in achieving targets (e.g. blood pressure below target range despite escalating support).</li> <li>causing symptomatic changes.</li> <li>during recent mobilisation change in posture.</li> <li>Recent onset arrhythmia with or without haemodynamic instability.</li> <li>Signs of hypovolaemia/inadequate perfusion.</li> <li>Evidence of impaired cardiac output.</li> <li>Pericardial tamponade/pulmonary support (e.g. pacing).</li> <li>Any recent/contingent signs of myocardial ischaemia/infarction?</li> </ul>	<ul style="list-style-type: none"> <li>These are examples rather than an exclusive list. There may be other specialist considerations in your environment that will add to risk.</li> <li>Staff inexperience</li> <li>Any first mobilisation treatment on a vasopressor.</li> <li>Previous adverse events during mobilisation.</li> <li>Adolescent</li> <li>Severe dyspnoea.</li> <li>Higher ventilation support e.g. high FiO2 and PEEP requirements.</li> <li>Autonomic dysregulation.</li> <li>Active organ ischaemia that is new or acute (less than 6 hours).</li> <li>ECMO / Intra-aortic balloon pump?</li> <li>Inadequate analgesia.</li> <li>If mobilisation has been specifically limited post-surgery (e.g. open abdomen) or because of injuries.</li> <li>Reduced conscious level.</li> </ul>	



# TAKE HOME MESSAGES

- ✦ EARLY MOBILIZATION IS FEASIBLE IN ICU PATIENTS, EVEN IN THE MOST EXTREME PATIENTS
- ✦ MONITORING IS PARAMOUNT
- ✦ MD, NURSES, PT, OT, ...  
TO BE SAFE, WE NEED ENOUGH PEOPLE
- ✦ WE HAVE TO REMAIN CAUTIOUS WHEN ANALYZING THE LITTERATURE

